Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (91-100 of 484) with videos related to

Pageof 49
Sort By:
European Urology|February 10, 2009
Pharmacological approaches to reducing the risk of prostate cancerRoger S Rittmaster, Neil E Fleshner, Ian M Thompson
Nature Reviews. Clinical Oncology|November 28, 2013
Future directions in the prevention of prostate cancerIan M Thompson, April B Cabang, Michael J Wargovich
The New England Journal of Medicine|November 15, 2013
Survival in the prostate cancer prevention trialCatherine M Tangen, Phyllis J Goodman, Ian M Thompson
JAMA|August 5, 2014
Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision makingIan M Thompson, Robin J Leach, Donna P Ankerst
Urologic Oncology|February 4, 2018
Organizing a clinical trial for the new investigatorJanet Baack Kukreja, Ian M Thompson, Brian F Chapin
The New England Journal of Medicine|May 16, 2019
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. ReplyPhyllis J Goodman, Catherine M Tangen, Ian M Thompson
Asian Journal of Andrology|June 11, 2014
Re: Long-term survival of participants in the Prostate Cancer Prevention TrialIan M Thompson, Catherine M Tangen, Phyllis J Goodman
JAMA|January 9, 2014
Changing the terminology of cancer--replyLaura J Esserman, Ian M Thompson, Brian J Reid
The Journal of Urology|August 21, 2002
Impact of previous local treatment for prostate cancer on subsequent metastatic diseaseIan M Thompson, Catherine Tangen, Joseph Basler, et al.
The Journal of Urology|August 19, 2008
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancerIan M Thompson, Donna P Ankerst, Ruth Etzioni, et al.
Pageof 49

Showing results (91-100 of 484) with videos related to

Sort By:
Pageof 49
European Urology|February 10, 2009
Pharmacological approaches to reducing the risk of prostate cancerRoger S Rittmaster, Neil E Fleshner, Ian M Thompson
Nature Reviews. Clinical Oncology|November 28, 2013
Future directions in the prevention of prostate cancerIan M Thompson, April B Cabang, Michael J Wargovich
The New England Journal of Medicine|November 15, 2013
Survival in the prostate cancer prevention trialCatherine M Tangen, Phyllis J Goodman, Ian M Thompson
JAMA|August 5, 2014
Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision makingIan M Thompson, Robin J Leach, Donna P Ankerst
Urologic Oncology|February 4, 2018
Organizing a clinical trial for the new investigatorJanet Baack Kukreja, Ian M Thompson, Brian F Chapin
The New England Journal of Medicine|May 16, 2019
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. ReplyPhyllis J Goodman, Catherine M Tangen, Ian M Thompson
Asian Journal of Andrology|June 11, 2014
Re: Long-term survival of participants in the Prostate Cancer Prevention TrialIan M Thompson, Catherine M Tangen, Phyllis J Goodman
JAMA|January 9, 2014
Changing the terminology of cancer--replyLaura J Esserman, Ian M Thompson, Brian J Reid
The Journal of Urology|August 21, 2002
Impact of previous local treatment for prostate cancer on subsequent metastatic diseaseIan M Thompson, Catherine Tangen, Joseph Basler, et al.
The Journal of Urology|August 19, 2008
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancerIan M Thompson, Donna P Ankerst, Ruth Etzioni, et al.
Pageof 49